Biliary tract cancer: a survey regarding the current oncological daily care practice in Germany

TY - JOUR

T1 - Biliary tract cancer: a survey regarding the current oncological daily care practice in Germany

AU - Sinn, Marianne

AU - Bischoff, Sven

AU - Nehls, Oliver

AU - Pelzer, Uwe

AU - von Weizsäcker, Fritz

AU - Kubicka, Stefan

AU - Stieler, Jens M

AU - Caca, Karel

AU - Riess, Hanno

PY - 2012

Y1 - 2012

N2 - BACKGROUND: The low incidence and the variable presentation complicate clinical investigations on biliary tract cancer. The results of Valle et al. in 2009 provided, for the first time, an evidence-based palliative treatment for this rare tumor type. So far no data are available in Germany regarding the current daily care practice.METHODS: We started this national survey in May 2011, including about 3,400 members of the AIO (Working Group Medical Oncology), DGHO (German Society of Hematology and Oncology) and GGHBB (Society of Gastroenterology and Hepatology in Berlin and Brandenburg). The standardized online form contained questions concerning field of action and diagnostic and therapeutic procedures. Evaluation was conducted anonymously.RESULTS: 162 responses could be obtained, corresponding to a response rate of about 5%. 70.4% of the respondents were physicians in hospitals, 23.5% stated to work in private practices. 61.7% of the respondents were medical oncologists and 27.2% gastroenterologists. 52.5% of the participants pointed out to use the standard regimen of gemcitabine and cisplatin. For second-line regimen, the most frequent answer (29%) specified the administration of oxaliplatin in combination with 5-fluorouracil (5-FU) or capecitabine.CONCLUSIONS: This survey may help to clarify the current oncologic daily care procedures for patients with biliary tract cancer in Germany. The results can be helpful for further clinical investigations or the implementation of a tumor-specific register.

AB - BACKGROUND: The low incidence and the variable presentation complicate clinical investigations on biliary tract cancer. The results of Valle et al. in 2009 provided, for the first time, an evidence-based palliative treatment for this rare tumor type. So far no data are available in Germany regarding the current daily care practice.METHODS: We started this national survey in May 2011, including about 3,400 members of the AIO (Working Group Medical Oncology), DGHO (German Society of Hematology and Oncology) and GGHBB (Society of Gastroenterology and Hepatology in Berlin and Brandenburg). The standardized online form contained questions concerning field of action and diagnostic and therapeutic procedures. Evaluation was conducted anonymously.RESULTS: 162 responses could be obtained, corresponding to a response rate of about 5%. 70.4% of the respondents were physicians in hospitals, 23.5% stated to work in private practices. 61.7% of the respondents were medical oncologists and 27.2% gastroenterologists. 52.5% of the participants pointed out to use the standard regimen of gemcitabine and cisplatin. For second-line regimen, the most frequent answer (29%) specified the administration of oxaliplatin in combination with 5-fluorouracil (5-FU) or capecitabine.CONCLUSIONS: This survey may help to clarify the current oncologic daily care procedures for patients with biliary tract cancer in Germany. The results can be helpful for further clinical investigations or the implementation of a tumor-specific register.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Biliary Tract Neoplasms/diagnosis

KW - Cisplatin/therapeutic use

KW - Deoxycytidine/analogs & derivatives

KW - Endoscopy/statistics & numerical data

KW - Female

KW - Fluorouracil/therapeutic use

KW - Germany/epidemiology

KW - Health Care Surveys

KW - Humans

KW - Male

KW - Medical Oncology/statistics & numerical data

KW - Middle Aged

KW - Organoplatinum Compounds/therapeutic use

KW - Oxaliplatin

KW - Palliative Care/statistics & numerical data

KW - Practice Patterns, Physicians'/statistics & numerical data

KW - Treatment Outcome

KW - Young Adult

U2 - 10.1159/000345115

DO - 10.1159/000345115

M3 - SCORING: Journal article

C2 - 23207621

VL - 35

SP - 755

EP - 760

JO - ONKOLOGIE

JF - ONKOLOGIE

SN - 0378-584X

IS - 12

ER -